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Introduction
The central region of the retina, known as the macula, is 
responsible for central and colour vision [1] and is yellow 
in colour (hence macula lutea) due to the accumulation 
of the carotenoids lutein (L), zeaxanthin (Z) and meso-
zeaxanthin (MZ) (Fig. 1a) [2], where these compounds 
are collectively referred to as macular pigment (MP). The 
short-wavelength (blue) light-filtering properties of MP 
are important for optimal vision (because of consequential 
attenuation of chromatic aberration and the adverse impact 
of light scatter) [3, 4] and also confer photoprotection to 
the central retina because short-wavelength (blue) light is 
the most injurious of visible wavelengths. Further, the mac-
ular carotenoids actively quench damaging free radicals, 
and this antioxidant effect is maximized when all three 
carotenoids are present [5].
L and Z are consumed in a typical diet containing fruits 
and leafy green vegetables, whereas MZ has not been 
detected in collard greens [6]. It has been reported that 
in a typical Western diet, intake of L is between 1.0 and 
3.6 mg/day and intake of Z is circa 0.1 mg/day [7, 8]. How-
ever, MZ has been detected in liver of frog and quail [9] 
and more recently in trout flesh [10]. In the retina, there is 
evidence that macular MZ is derived (at least in part) from 
retinal L [11, 12], and given the scarcity of dietary sources 
of MZ, it is likely that most of retinal MZ is formed from 
L, but further work is needed to confirm this hypothesis 
[13–15].
In the vast majority of subjects, MP can be augmented 
following supplementation with MP’s constituent carot-
enoids [16], suggesting less-than-saturation levels in a 
substantial proportion of the population. Of note, commer-
cially available supplements used for eye health declare 
concentrations between 2 and 22 mg of total carotenoid. 
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However, the ratio of the respective macular carotenoids 
used in these formulations differs between products. 
There are a large number of trials reporting on the impact 
of supplementation with at least two of the three macular 
carotenoids (typically 10 mg/day of L and 2 mg/day of Z), 
and there is strong evidence that supplemental L and Z ben-
efit patients with non-advanced age-related macular degen-
eration (AMD), both in terms of disease progression and in 
terms of visual loss [17, 18]. However, a formulation con-
taining all three macular carotenoids (typically 10 mg/day 
of L, 2 mg/day of Z and 10 mg/day of MZ) does appear to 
offer some advantages in terms of augmentation of macular 
pigment across its spatial profile, and in terms of improve-
ments in visual performance in diseased [19, 20] and non-
diseased eyes [21]. Further, given the relatively recent com-
mercial availability of MZ for inclusion in formulations, 
there is need to assess its inclusion (whether overt, covert 
or inadvertent) in commercially available formulations con-
taining the macular carotenoids.
In order to generate a dietary supplement, manufacturers 
may obtain L and MZ from a number of source companies, 
which in turn obtain them from the petals of the marigold 
flower (Tagetes erecta). In order to extract L, the marigold 
petals are submitted to a saponification process that liber-
ates L of linked fatty acids (Fig. 1b). In order to produce 
MZ, the saponification process is modified to isomerize L 
to MZ through a double-bond migration that turns the ε-ring 
into a β-ring [22, 23] (Fig. 1c). In order to produce Z, several 
sources can be used, including hybrid varieties of marigold 
containing high concentrations of Z [24], paprika (Capsicum 
annuum) [25], wolfberry (Lycium barbarum) [26], Flavo-
bacterium multivorum [27] and the fruit Sastra (Garcinia 
intermedia) as a newly identified rich source of this carot-
enoid [28]. Moreover, it has recently been suggested that 
some companies have used MZ as a substitute for Z, perhaps 
prompted by the commercial observation that MZ is cheaper 
to source than Z, given that these carotenoids cannot be dis-
tinguished with standard HPLC techniques [29].
We have reported the presence of undeclared MZ in 
commercially available eye care formulations in the past 
[30], and that observation prompted us to conduct the cur-
rent study on concordance between declared and actual 
concentrations of the macular carotenoids in commercially 
available formulations and to investigate the implications 
of our observations for possible sources of undeclared MZ 
in such supplements. We believe that this study is impor-
tant, primarily because it will help facilitate the investiga-
tion of agreement between declared and actual concentra-
tions of the carotenoids present in commercially available 
eye supplements. The results from this study will also have 
important implications for designing and interpreting clini-
cal studies where supplementation with the macular carot-
enoids is under investigation. Finally, the information ema-
nating from this study will inform eye care specialists on 
their choice of a commercially available formulation for 
their patients.
Fig. 1  Structure of the three macular carotenoids and processes 
performed to obtain lutein and meso-zeaxanthin from marigold. a 
Structure of lutein [(3R,3’R,6’R)-β,ε-Carotene-3,3’-diol], zeaxanthin 
[(3R,3’R)-β,β-Carotene-3,3’-diol] and meso-zeaxanthin [(3R,3’S)-
β,β-Carotene-3,3’-diol]. b Lutein production process from marigold 
petals with saponification conditions described previously [33]. c 
meso-zeaxanthin production process from marigold with saponi-
fication conditions as described previously [34]. Lutein diester is 
attacked by one hydroxyl group (OH−) at carbon C6´ to trigger the 
conversion of the ε-ring to a β-ring, as suggested by Andrewes et al. 
[23]. n stands for 6, 7 or 8 repetitions of the two carbons included in 
the brackets, indicating that the fatty acid can be miristic, palmitic or 
stearic acid




In this study, we measured the carotenoid content of nine 
commercially available formulations containing the macu-
lar carotenoids (Table 1). Three batches, different in terms 
of expiry date, were sourced for each product and analysed 
(in triplicate) in order to investigate possible variability 
between batches. All formulations were presented as soft 
gel capsules, with the carotenoids suspended in fish oil or 
vegetable oil. Of note, some formulations also contained 
multivitamins and/or co-antioxidants.
We determined that MacuHealth with LMZ3® and 
MacuShield® use L, Z and MZ from IOSA (Industrial 
Orgánica S.A., Monterrey, Nuevo León, Mexico), whereas 
(where known) the rest of the formulations use the product 
FloraGLO® Lutein (Kemin Industries, Inc., Des Moines, 
IA, USA). Only Ocuvite® L Plus did not specify the source 
of carotenoids used on the product label. Eyepromise 
Table 1  Concentration of lutein (L), zeaxanthin (Z) and meso-zeaxanthin (MZ) in eye care supplements
Carotenoid amounts are provided in mg/capsule ± standard deviation, and as percentage of declared concentration achieved, including 95 % 
confidence interval
a Sourced in pharmacy
b Sourced online
c Sourced in health food store
d Sourced by the manufacturer
* Carotenoid not declared in product label, nd, carotenoid not detected
– Non-applicable
#  Quantification not including esterified Z
Supplement name, manufacturer, carotenoid supplier Batch number Months expiry Carotenoids (mg/capsule) % Achieved (95 % confidence)
Declared Measured
Preservision AREDS2®b 2710E0566 16 L 5 6.05 ± 0.27 121 (117–125)
Bausch + Lomb®└ 2936E0566 16 Z 1 1.63 ± 0.11 163 (155–172)
Floraglo® Lutein 2939E0566A 16 MZ * nd –
VitaluxPlus®a E02010 13 L 10 11.12 ± 0.52 111 (107–115)
Alcon® E05507 16 Z 2 1.03 ± 0.07 52 (49–54)
Floraglo® Lutein E03745 15 MZ * 0.10 ± 0.01 –
Nutrof®omegaa V067 10 L 10 9.54 ± 0.67 95 (90–101)
Spectrum Thea® V070 12 Z 2 1.30 ± 0.27 47 (44–50)
Floraglo® Lutein V063 8 MZ * 0.94 ± 0.08 –
Ultra Lutein®a,c 1266679 17 L 20 20.78 ± 0.73 104 (101–107)
Nature’s Plus® 1263243 14 Z 0.86 2.13 ± 0.09 248 (240–256)
Floraglo® 1268878 17 MZ * 0.18 ± 0.03 –
Eyepromise Restore®b C1401047 28 L 4 4.83 ± 0.14 121 (118–123)
Zeavision® H13059 22 Z 8 1.28 ± 0.07# 16 (15–17)
Floraglo® Lutein, Zeagold® B14045 28 MZ * 0.04 ± 0.01 –
CentroVision® L fortea 5054 15 L 14 13.91 ± 0.45 99 (97–102)
OmniVision GmbH® 4581 10 Z 1.04 1.68 ± 0.08 161 (156–167)
Floraglo® Lutein 8180 10 MZ * 0.11 ± 0.01 –
MacuHealth with LMZ3® d 110614 29 L 10 10.89 ± 1.34 109 (99–119)
Macuhealth LLC® 160314 26 Z 2 2.19 ± 0.49 109 (90–128)
IOSA® 330913 20 MZ 10 12.15 ± 2.14 122 (105–138)
MacuShield® d 116215 11 L 10 12.11 ± 0.91 121 (114–128)
Macuvision Europe® 118860 21 Z 2 2.51 ± 0.25 126 (116–135)
IOSA® 120480 26 MZ 10 12.70 ± 0.74 127 (121–133)
Ocuvite® L Plusa D09592 10 L 5 5.53 ± 0.26 111 (107–115)
Bausch + Lomb® D09588 10 Z 1 0.60 ± 0.03 60 (57–62)
Unknown D09591 10 MZ * 0.79 ± 0.03 –
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Restore® was the only supplement to specify a source of Z 
(Zeagold®, Calsek Inc., Kalamazoo, MI, USA).
Carotenoid standards and solvents
L standard [(3R,3’R,6’R)-β,ε-Carotene-3,3’-diol] and Z 
standard (racemic mixture of the three Z enantiomers: 
(3R,3’R)-β,β-Carotene-3,3’-diol), (3S,3’S)-β,β-Carotene-
3,3’-diol and (3R,3’S)-β,β-Carotene-3,3’-diol) were sup-
plied by CaroteNature GmbH (Ostermundigen, Swit-
zerland). The Standard Reference Material (SRM) 968e 
(Fat-Soluble Vitamins, Carotenoids, and Cholesterol in 
Human Serum) was obtained from NIST (National Insti-
tute for Standards and Technology, Gaithersburg, MD, 
USA). The solvents THF (tetrahydrofuran), methanol, 
MTBE (methyl tert-butyl ether), hexane and isopropanol, 
all HPLC grade, were purchased from Sigma-Aldrich (Vale 
Road, Arklow, Wicklow, Ireland) or Thermo Fisher Sci-
entific (Blanchardstown Corp Pk 2, Ballycoolin, Dublin, 
Ireland). BHT (butylated hydroxytoluene) was purchased 
from Sigma-Aldrich.
Statistical methods
The statistical software package SPSS 20 was used for 
analysis. The focus of the study was on agreement between 
declared and actual carotenoid content for each supplement 
and on variation in this agreement between batches of sup-
plements. The study also investigated, for each supplement, 
achievement of target ratios for the respective carotenoids. 
As the formulations varied widely in terms of declared 
values (e.g. from 4 mg up to 20 mg for L), analysis was 
largely confined to data representing percentage agreement 
with declared values and achievement (at a minimum) of 
declared content of each respective carotenoid. Confidence 
intervals for mean percentage agreement for each formu-
lation were generated in order to identify those supple-
ments which failed to achieve close to 100 % agreement 
with declared carotenoid content. Between-batch variation, 
in terms of percentage agreement, was investigated using 
analysis of variance, separately for each supplement, with 
batch as a random factor. Achievement of target carotenoid 
ratios, for each supplement, was investigated by generation 
of confidence intervals for these ratios. The 5 % level of 
significance was used in all analyses, without adjustment 
for multiple tests, e.g. 95 % confidence intervals were used 
throughout. Confidence intervals were constructed treating 
the nine sample values for each supplement as independ-
ent, i.e. ignoring inter-batch variation, which was gener-
ally small. Data from different batches were also combined 
for regression analysis of the relationship between L con-
centration and undeclared MZ concentration in certain 
formulations.
HPLC analysis
L, Z and MZ were separated and quantified on an Agilent 
Technologies (Palo Alto, CA) 1260 Series HPLC system 
equipped with a Diode Array Detector (DAD, G1315C), 
binary pump, degasser, thermostatically controlled col-
umn compartment, thermostatically controlled high-per-
formance autosampler (G1367E) and thermostatically 
controlled analytical fraction collector. For system control 
and data processing, the software ChemStation for LC3D 
systems Rev. B.04.03-SP1 [87] (Agilent Technologies) was 
used. The standard injection volume was 10 µL.
System 1 (for carotenoid quantification) was performed 
using a Daicel Chiralpak AD-H column, composed of 
amylose tris (3,5-dimethylphenylcarbamate) coated on 
5 μm silica gel (250 × 4.6 mm i.d.; Chiral Technologies 
Europe, Cedex, France). The column was protected with a 
guard column containing a guard cartridge with the same 
chemistry of the column (10 × 4 mm i.d. 5 µm). Isocratic 
elution was performed with hexane and isopropanol (95:5, 
v/v) and a flow rate of 1 mL min−1. The column tempera-
ture was set at 25 °C.
System 2 (for carotenoid ester analysis) was performed 
using a C30-reversed phase column (250 × 4.6 mm i.d., 
3 µm; YMC Europe, Dinslaken, Germany) with a guard 
column containing a guard cartridge with the same chem-
istry of the column (10 × 4 mm i.d., 3 µm). The flow rate 
was 1 mL min−1 with a linear gradient from 100 % A 
(methanol: methyl tert-butyl ether:water (30:10:1, v/v/v)) 
to 20 % B (methanol: methyl tert-butyl ether (1:1, v/v)) 
within 10 min, then to 100 % B within 1 min, maintain-
ing this condition for another 24 min. The solvents were 
returned to the starting conditions within 1 min, and the 
column temperature was set at 25 °C.
Sample preparation
Sample extraction and preparation were performed under 
protective amber light provided by LED lamps installed 
in our laboratory (Philips BCP473 36xLED-HB/AM 100-
277 V) in order to prevent carotenoid isomerization. The 
antioxidant BHT was added to the extraction solvents to 
prevent carotenoid degradation. For each supplement, a sin-
gle capsule was selected at random and placed in a 50-mL 
polypropylene tube containing 10 mL of THF with 0.1 % 
BHT. The capsule was broken with a blade, allowing the 
content to flow into the THF. The blade was washed with 
10 mL of THF to reach a final volume of 20 mL. Each 
tube was vortexed for 10 s, sonicated at 24 °C for 2 min 
and vortexed again for 10 s, in order to efficiently separate 
the capsule contents from the shell. The tubes were centri-
fuged at 4700 rpm at 25 °C without brake to avoid resus-
pension of the pellet. Different dilutions of each tube were 
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then prepared for the following purposes: detection of MZ, 
dilution 1:10; quantification of Z and MZ, dilution 1:100; 
quantification of L, dilution 1:600. 0.2 mL of each dilution 
prepared were dried in a centrifugal vacuum concentrator 
(GeneVac MiVac Duo Concentrator, Ipswich, England) and 
resuspended in 2 mL of HPLC mobile phase.
We analysed the supplements using HPLC system 2 and 
verified the presence of non-esterified carotenoids (Fig. 2), 
thereby precluding the need for saponification. However, 
for one supplement (EyePromise Restore) we identified 
esterified Z in the formulation, and, given that esterified 
Z was not quantified as part of this study, this supplement 
was not included in analyses regarding this carotenoid.
In order to validate the method, we performed a recovery 
assay of L using the product Ultra Lutein® and L standard 
as described previously [31]. We carried out the assay in 
duplicate, and the extraction efficiency was 95.2 ± 2.3 %.
Calibration
We confirmed the accuracy of our HPLC system using the 
Standard Reference Material 968e level 2 (NIST) in HPLC 
system 2. L measured was 0.098 µg mL−1, which is within 
the limits of the certified value reported by NIST for this 
carotenoid (0.097 ± 0.007 µg mL−1).
Quantification was achieved by constructing two stand-
ard curves, one for L and one for Z and MZ, using a UV–
Vis spectrophotometer UVmini-1240 (Shimadsu) and 
HPLC system 1, with the DAD detector set to 450 nm. 
For the standard L curve, L was previously purified in our 
laboratory up to 94 % purity (based on peak area). Seven 
concentrations were measured in triplicate within a lin-
ear range 0.4–3.6 mg L−1, and the molar extinction coef-
ficient applied was 147.3 × 103 L mol−1 cm−1 in hexane 
[32]. The resulting regression line was given by the formula 
y = 10.70x − 15.22 (r2 = 0.998), where x is L concen-
tration and y is the peak area. For the Z and MZ standard 
curve, the MZ enantiomeric mix from Carotenature was 
used (95 % purity based in peak area, system 2). Identical 
spectral characteristics were assumed for the three enanti-
omers present in the standard; therefore, a Z molar extinc-
tion coefficient was applied, 141.1 × 103 L mol−1 cm−1 
in hexane (Davies, 1976). Seven concentrations within a 
linear range 0.15–1.4 mg L−1 were used, and the resulting 
regression line was given by the formula y = 10.05x − 5.91 
(r2 = 0.997), where x is Z concentration and y is the peak 
area.
We established the limit of quantification (LOQ) of our 
HPLC system for L and Z assessing the lowest concentra-
tion of each carotenoid quantifiable with a relative standard 
deviation (RSD) lower than 5 % (11 sample injections per 
carotenoid). LOQ was 0.62 ng for L (RSD = 3.1 %) and 
0.15 ng for Z (RSD = 4.7 %).
Inter‑batch variability
In order to investigate the representativeness of our findings 
and the homogeneity of different batches, we measured 
the macular carotenoid content of three different batches 
of each formulation and assessed inter-batch homogene-
ity, of total carotenoid content measured, by analysis of 
variance with batch as a random factor. For one product, 
MacuHealth with LMZ3®, this analysis suggested statisti-
cally significant inter-batch differences in terms of percent-
age of total macular carotenoid content (P = 0.011); for 
this formulation, the amount of total carotenoids ranged 
from an average of 97.5 % of declared content for one 
batch, up to 133.2 % for another batch. None of the other 
Fig. 2  Detection of free carotenoids and carotenoid esters in the 
supplements using HPLC–DAD with a C30 column. Unesterified 
lutein (L), unesterified total zeaxanthin (tZ) and esterified zeaxanthin 
(peaks I–III as example). EP Eyepromise Restore®; PV Preservision 
AREDS2®; MH MacuHealth with LMZ3®; MS Macushield®; UL 
Ultra Lutein®; NO Nutrof®omega; VI Vitalux Plus®; OC Ocuvite® L 
Plus; CE CentroVision® L Forte
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formulations exhibited statistically significant inter-batch 
variability in terms of total carotenoid content. These 
results suggest that, for almost all formulations, inter-batch 
variability was not responsible for the findings reported 
herein, and, further, that the generation of confidence inter-
vals could be legitimately based on treating the data as nine 
independent observations for each formulation. Moreo-
ver, although MacuHealth with LMZ3® did exhibit inter-
batch differences, it should be noted that even in the poor-
est batch of this formulation, the 95 % confidence interval 
(67–123 %) comfortably included 100 % of total declared 
carotenoid content.
Results
Concordance of each carotenoid to declared label 
concentrations
Table 1 presents the concentrations (mean ± SD of nine 
samples) of L and Z calculated for each formulation tested, 
along with per cent of target achieved and 95 % confidence 
intervals.
Declared and measured ratios of L:Z and L:MZ
Table 2 presents the ratio of L:Z and L:MZ for each formu-
lation tested, along with 95 % confidence intervals.
Detection of undeclared MZ and its presence 
in FloraGLO® Lutein
As shown in Fig. 3, we report that in six of seven prod-
ucts not declaring MZ, we found a peak on the HPLC 
chromatogram with the same spectrophotometric charac-
teristics of MZ. Only for Preservision AREDS2®, we can-
not assert whether MZ is present (or indeed absent) in this 
formulation, due to the quality of the spectra obtained from 
the putative MZ peak found in this supplement (Fig. 3c, 
peak II). The identity of the putative MZ peaks detected 
was confirmed by a spiking experiment performed with one 
of the formulations (Ultra Lutein®) using the MZ standard 
(Fig. 4). MZ concentration was quantified for these supple-
ments (Table 1).
Five of these six products used the same L source (Flo-
raGLO® Lutein), suggesting that this carotenoid is present 
in this L source. Regression analysis, to test the relation-
ship between detected MZ and L (using the four products 
containing MZ below 1 % of total carotenoid content), 
revealed a strong positive and statistically significant rela-
tionship, suggesting that the amount of undeclared MZ 
is related to the concentration of L in these supplements 
(see Fig. 5, regression formula MZ = 0.0083L + 0.0017; 
r2 = 0.86; P < 0.001).
Discussion
In this study, we tested the concordance of L, Z and MZ 
concentrations to product label claim. We found that most 
of the formulations contained L concentrations higher 
than declared, with the exception of Nutrof®omega and 
CentroVision® L forte, but it should be noted that even 
for these two formulations, the 95 % confidence intervals 
did include the declared concentration [Nutrof®omega, 
95.4 % (90.2–100.5 %); CentroVision® L forte, 99.3 % 
(96.8–100.8 %), see Table 1]. Of note, the highest concen-
tration of L detected in any of the formulations tested was 
Table 2  Carotenoid ratios in 
eye care supplements
Declared lutein:zeaxanthin ratios (L:Z) and lutein:meso-zeaxanthin ratios (L:MZ) were obtained by divid-
ing the amount of declared L by the amount of declared Z or MZ, respectively. Measured ratios were 
obtained from the amounts of quantified L, Z and MZ. 95 % confidence intervals are displayed
* Bias in the measured L:Z ratio (esterified Z not quantified for this supplement)
– Non-applicable, MZ is not declared by the supplement
Supplement L:Z L:MZ
Declared Measured Conf. interval Declared Measured Conf. interval
EyePromise restore® 0.5 3.8* – – 113.0 –
Ultra Lutein® 23.3 9.8 (9.4, 10) – 116.5 –
CentroVision® L forte 13.5 8.3 (8.0, 8.5) – 132.7 –
VitaluxPlus® 5 10.8 (10.4, 11.3) – 111.4 –
Ocuvite® L Plus 5 9.3 (8.9, 9.6) – 7.0 –
Nutrof®omega 5 10.1 (9.7, 10.6) – 7.4 –
Preservision AREDS2® 5 3.7 (3.6, 3.8) – – –
MacuHealth with LMZ3® 5 5.0 (4.6, 5.6) 1 0.91 (0.81, 0.99)
MacuShield® 5 4.8 (4.7, 5.0) 1 0.95 (0.92, 0.996)
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only 121 % of declared content for three of them, suggest-
ing that the concentrations of L are tightly and sparingly 
controlled by manufacturers. Thus, we report that all nine 
supplements achieved close to or slightly above-declared L 
concentrations.
With respect to MZ, the two formulations declaring this 
carotenoid (Macuhealth with LMZ3® and Macushield®) 
achieved their target MZ concentrations. Indeed, even in 
the batch of Macuhealth with LMZ3® containing the lowest 
concentrations of total carotenoids (97.5 %), MZ content 
was 104 % of declared content.
With respect to Z, Macuhealth with LMZ3® and 
Macushield® contained Z concentrations higher than 
declared, whereas Ocuvite® L Plus, whose carotenoid 
Fig. 3  Detection of MZ in the supplements by chiral HPLC–DAD. 
A commercial standard containing a zeaxanthin racemic mixture, 
including (3S,3’S)-zeaxanthin (SZ), (3R,3’S)-zeaxanthin (MZ) 
and (3R,3’R)-zeaxanthin (RZ) was run, and the resulting chroma-
togram was overlaid (represented in grey) to the chromatograms of 
the supplements. Peak I, tentatively classified as oxo-lutein; peak II, 
(3R,3’S)-zeaxanthin (MZ); peak III, (3R,3’R)-zeaxanthin (RZ); peak 
IV, lutein (L). The insets represent the spectra of the peaks selected, 
specifying the maxima absorption wavelength (wavelength range 
350–550 nm). EP Eyepromise Restore®, PV Preservision AREDS2®, 
MH MacuHealth with LMZ3®, MS Macushield®, UL Ultra Lutein®, 
NO Nutrof®omega, OC Ocuvite® L Plus, VI Vitalux Plus®, CE Cen-
troVision® L Forte
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source is not known, did not contain the concentration of 
Z declared on their product label (with only 60 % of the 
declared concentration detected in our experiment). In the 
formulations using FloraGLO® Lutein, two formulations 
failed to achieve their Z target by substantial amounts (Vita-
luxPlus® and Nutrof®omega, showing Z concentrations of 
47 and 52 % of declared content, respectively). However, 
the rest of the formulations using FloraGLO® Lutein con-
tained concentrations of Z much higher than the declared 
content, ranging from 161 % in CentroVision® L forte 
to 248 % in Ultra Lutein®. These disparities in Z content 
(47–248 % of declared content) are somewhat unexpected, 
given that the concentrations of L in these supplements did 
not diverge much (95–121 %) from their declared concen-
trations, and both of these carotenoids were provided by 
FloraGLO® Lutein (i.e. FloraGLO® Lutein was the source 
of L and Z for these products).
Also, we calculated the L:Z ratio for each product and 
compared it to the respective declared L:Z ratio. As given 
in Table 2, the 95 % confidence intervals for the L:Z ratio 
indicate that three supplements (Ultra Lutein®, CentroVi-
sion® L forte and Preservision AREDS2®) are significantly 
below their target ratio, and three supplements (Vitalux-
Plus®, Ocuvite® L Plus and Nutrof®omega) are signifi-
cantly above their target ratio for L:Z. The origins of this 
over- or under-achievement are evident from the final col-
umn of Table 1. For example, for Ultra Lutein®, L is 104 % 
of target claim, whereas Z is 248 % of target claim, and the 
L:Z ratio is therefore much lower than declared. Accord-
ingly, it appears that the reason for the observed discord-
ance between declared and measured L:Z ratio in these 
products is mistaken declaration of Z concentration in these 
formulations. Of note, the 95 % confidence intervals for 
the L:Z ratio indicate that Macuhealth with LMZ3® and 
Macushield® achieved their declared ratio. It is important to 
point out that both of these products obtain their carotenoid 
blend from the same company (Industrial Orgánica S.A.). 
With respect to the L:MZ ratio for these formulations, they 
are marginally below target, and it appears that the reason 
for this finding is that the manufacturers declare the same 
concentration (10 mg per capsule) for each of these carote-
noids, but the measured MZ concentrations are higher than 
the measured L concentrations in both products.
One of the most interesting and important findings from 
our study was the detection of MZ in products not declar-
ing this carotenoid on the product label. Importantly, where 
MZ was detected, it was present in each of the three batches 
analysed for each formulation. Further, because we avoided 
saponification in our process, the observed MZ cannot be 
attributed to artifactual generation from L by our extraction 
method. To our knowledge, this is the first study to identify 
and quantify undeclared MZ in eye care formulations con-
taining the macular carotenoids. The finding of MZ in five 
out of six products using FloraGLO® Lutein and the strong 
correlation between measured L and MZ in four of these 
supplements suggests that this carotenoid is present in this 
source of L. Indeed, based upon the regression formula 
obtained, a supplement containing 10 mg of L per capsule 
from FloraGLO® Lutein would contain circa 0.085 mg of 
MZ.
Fig. 4  Spiking of the putative meso-zeaxanthin peak of Ultra Lutein® 
with standard meso-zeaxanthin. In grey, HPLC profile of standard 
zeaxanthin enantiomeric mixture. UL, putative meso-zeaxanthin peak 
in Ultra Lutein®; UL + MZ, meso-zeaxanthin putative peak of Ultra 
Lutein® spiked with standard zeaxanthin enantiomeric mixture. IS 
internal standard (cantaxanthin)
Fig. 5  Lutein and meso-zeaxanthin concentrations measured in a 
selection of supplements sourcing FloraGLO® Lutein and least-
squares line of best fit. Each circle represents the lutein and meso-
zeaxanthin concentration measured in a single capsule; nine single 
measurements from three different batches are represented for each 
formulation. EP Eyepromise Restore®, VI Vitalux Plus®, CE Centro-
Vision® L Forte, UL Ultra Lutein®
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The presence of small amounts of undeclared MZ in L 
sources (below 1 % in FloraGLO® Lutein) is likely una-
voidable due to the saponification process performed to 
generate L. However, these low concentrations of MZ 
reported should not be dismissed, from either a clini-
cal or research perspective, as it has been shown that MZ 
was detected in the serum of subjects after supplementa-
tion with Ultra® Lutein daily for 4 weeks [30]. We believe 
that it is important that MZ is declared on the product label 
(even if it is present in small concentrations) of formula-
tions that do indeed contain this carotenoid.
Of interest, the formulation Nutrof®omega contains 
MZ concentrations higher than expected for a supplement 
using FloraGLO® Lutein, and a similar result is exhib-
ited by Ocuvite® L Plus, whose carotenoid source is not 
known. We reported that these two formulations, together 
with VitaluxPlus®, contained only circa 50 % of declared 
Z. We hypothesize that the manufacturers of Ocuvite® L 
Plus and Nutrof®omega added (covertly or inadvertently) 
MZ in an attempt to achieve the declared Z content and L:Z 
ratio; however, we have no direct evidence to support this 
statement. This practice has been previously reported [29] 
where it was suggested that this was performed because 
MZ is less expensive than Z.
Conclusion
In conclusion, each commercially available formulation 
tested achieved a minimum of declared L content, but 
this was not the case for Z, with a high degree of varia-
tion between formulations. Six of seven formulations with 
undeclared MZ contained this carotenoid across several 
batches of product tested, probably as a result of using 
FloraGLO® Lutein in at least four of them. This indicates 
that a greater degree of regulation is required for the use 
of commercially available supplements containing the 
macular carotenoids, and greater transparency by producers 
with respect to the source of the respective carotenoids is 
advised.
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